CatenaBio’s Post

Merck KGaA has entered into a significant partnership with an AI-focused biotech company to advance the development of antibody-drug conjugates (ADCs), a cutting-edge area in cancer treatment. This collaboration, valued at $376 million, underscores the growing importance of AI in biotechnology. By leveraging AI, the partnership aims to enhance the precision and efficiency of ADC development, which involves linking potent anti-cancer drugs to antibodies that specifically target cancer cells, minimizing damage to healthy tissues. This strategic move by Merck KGaA highlights the potential of AI to accelerate drug discovery and development, promising more effective and personalized treatment options for cancer patients. Full article here from Fierce Biotech: https://lnkd.in/eT8QJcJB #Biotech #Healthcare #AI #DrugDiscovery #Treatment #Cancer

🌟 Introducing the RETOS Project in Collaboration with UAB and Sant Pau 🌟 We are excited to share with our network the ongoing project in partnership with the IBB UAB and the Institut de Recerca Sant Pau! We are proud to lead the consortium and participate in this project financed by the Agencia Estatal de Investigación from Spain’s Ministerio de Ciencia, Tecnología e Innovación (Retos public-private collaboration program). 🔍 Project Insights The primary goal of this project is to develop a tumor-agnostic therapy targeting CXCR4+ patients with various types of metastatic cancer using a novel protein-based drug. This therapy aims to benefit metastatic patients overexpressing the CXCR4 receptor, regardless of the location of the primary tumor. 💡 Why This Matters This proposal addresses the critical issue of the lack of selectivity in current cytotoxic drug administration, which results in unwanted toxicity, limits the therapeutic index, and allows metastasis to progress. Our project aims to develop a drug that can efficiently kill cancer cells responsible for metastasis without harming non-tumor tissues. This represents a new class of safer, targeted cytotoxic drugs based on an innovative biotechnological platform designed to treat highly aggressive CXCR4+ cancer types. #Nanoligent #UAB #InstitutdeRecercaSantPau #Nanotechnology #ProteinEngineering #Innovation #HealthcareInnovation #Biotech #Oncology

Exciting news from MImAbs SAS and Emergence Therapeutics ! We are pleased to share the promising results of the study on ETx-22, a novel nectin-4-directed antibody-drug conjugate (ADC), featured in Cancer Research Communications. ETx-22, an exatecan ADC, induced rapid and long–lasting tumor regression in various Patient Derived Xenograft models expressing low to high levels of nectin-4. ETx-22, was well tolerated in cynomolgus monkeys at doses ≤ 20 mg /kg with no significant skin toxicity. The first human study was launched in March 2024. Key MImAbs achievements in this project: antibodies generation and selection, antibody humanization, conjugation with exatecan, in vivo and ex vivo ADC stability assessment by LC/MS, in vivo efficacy in Cell Line Derived Xenograft models. MImAbs SAS is proud to have contributed to this project, supported by the collaboration of: -  CRCM - Centre de Recherche en Cancérologie de Marseille, France -  Institut Paoli-Calmettes, Marseille, France -  Heidelberg Pharma AG, Ladenburg, Germany - Emergence Therapeutics, now a wholly owned subsidiary of Eli Lilly and Company To see the full study : https://lnkd.in/dj9nXrrg #ADC #AntibodyDrugConjugates #PatientDerivedXenograft #CellLineDerivedXenograft #Nectin4 #Exatecan #AntibodyGeneration #AntibodyHumanization

Conditionally activated bispecifics are making a splash! Message me to learn more about what ibio is working on.

🚀 Exciting news from PDX Pharmaceuticals! They have been awarded $160,652 by the U.S. Department of Health and Human Services (HHS)  , The National Institutes of Health, National Cancer Institute. This grant will help advance the commercialization readiness of their innovative nanoparticle-based immunotherapy for non-small cell lung cancer (NSCLC). Their next-generation immunotherapy, ARAC-02, aims to improve the survival rate of NSCLC patients by co-delivering multiple therapeutic agents to target cancer cells and enhance the immune response. #SBIR #STTR #CancerResearch #Immunotherapy 🔬 PDX Pharmaceuticals is leveraging their expertise in nanotechnology and cancer systems biology to develop first-in-class combination immunotherapies. This project will focus on protecting intellectual properties and initiating GMP-compliant manufacturing of ARAC-02. The award will support their efforts for 1 year and 11 months, starting from September 5, 2024, to August 31, 2026. #Innovation #Healthcare #Biotech #Research

Jetze Tepe, PhD, directs Drug Discovery Services, a shared resource utilizing the latest technology to assist UVACCC researchers' scientific exploration and expertise. Drug Discovery Services assists researchers who seek to create new treatments or improve current options for cancer patients. But Drug Discovery Services doesn’t stop there. They also study how new or improved drugs could interact with the human body from absorption to metabolization and beyond. For Dr. Tepe, the Drug Discovery Services synergizes with his research, as he and his team target “undruggable proteins” to treat cancer. Dr. Tepe and his team specialize in transforming compounds into brand-new molecules. These molecules communicate with specific proteins in cancer cells causing them to dismantle or they can act as vehicles, delivering medications directly to tumor cells. Click here to learn more: https://bit.ly/3UQdVeb 

🔬 Breaking: Roche Inks $1.8B Deal with Flare Therapeutics in GroundCancer Research Partnership TL;DR: Roche and Flare Therapeutics join forces in a $1.8B+ strategic alliance, targeting novel cancer treatments through transcription factor modulation. Key Highlights: • Major investment signals growing confidence in transcription factor-based therapies • Partnership aims to revolutionize cancer treatment approaches • Deal reflects industry shift toward innovative biotech collaborations Strategic Implications: This partnership highlights a significant opportunity in the oncology space. Transcription factor targeting is emerging as a crucial frontier in cancer therapeutics, potentially opening new avenues for treatment development. 💡 Industry Impact: For biotech leaders, this signals an optimal time to: - Evaluate transcription factor-focused technologies - Consider strategic partnerships in this space - Reassess R&D priorities aligned with this emerging trend What are your thoughts on this strategic move? How do you see transcription factor targeting shaping the future of cancer therapeutics? #Biotech #CancerResearch #PharmaBusiness #Innovation BioDataStudio

This clip is part of a biopharma animation designed by our team that illustrates an innovative cancer therapeutic technology using antibodies and showcases its advantages in fighting against cancer. Our client's platform combines antibody specificity with cell-penetrating and DNA-binding abilities, creating a potent tool against cancer. Their technology has shown significant cancer cell-killing activity in preclinical studies. It enhances the effectiveness of DNA-damaging agents like chemotherapy and can be linked to nanoparticles for targeted drug delivery, reducing side effects. This technology also serves as a targeted imaging and therapeutic agent, offering a non-invasive approach for patient identification and treatment. Visit our site to learn more about our work 👉 biotech-animated.com #medicalanimation #biopharma #pharma #biotechnology #biotechresearch #molecularbiology #cancerresearch

𝐂𝐨𝐧𝐠𝐫𝐚𝐭𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬 𝐭𝐨 𝐀𝐤𝐨𝐲𝐚 𝐨𝐧 𝐚 𝐆𝐫𝐨𝐮𝐧𝐝𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲! Akoya Biosciences, Inc. PhenoCycler Fusion and PhenoImager HT platforms have been selected by the UK-based MANIFEST Consortium to analyze thousands of cancer tissue samples. This initiative aims to uncover biomarkers predicting immunotherapy success, advancing personalized cancer treatments. I believe this collaboration will significantly enhance our understanding of cancer and improve patient outcomes! What are your thoughts on the impact of spatial proteomics in advancing personalized cancer treatments? #cancerresearch #immunotherapy #spatialbiology #proteomics #biomarkers #oncology #healthcareinnovation #biotech #personalizedmedicine #clinicaltrials #researchcollaboration #drugdevelopment #scientificinnovation #cancerimmunotherapy #biopharma #clinicalresearch #pharmaceuticals #lifesciences #precisionmedicine #healthcare #akoyabiosciences

💡 Exciting Developments in Immuno-Oncology! 💡 Earlier this week, Janux Therapeutics announced positive Phase 1 data for JANX007, a masked T-cell engager targeting metastatic prostate cancer. These findings align with our preclinical observations and reinforce the potential of conditionally activated bispecifics like those developed with iBio’s ShieldTx™ technology. This allows us to target diseased tissue without harming healthy tissue. ShieldTx™ leverages machine learning and engineered epitopes to design conditionally active, masked antibodies. This technology ensures antibodies remain inactive until they reach diseased tissue, minimizing harm to healthy cells. Our approach goes further by repurposing epitopes as masks, mimicking natural targets, and improving safety and development timelines. At iBio, we’re advancing conditionally active therapies, including a Trop2 x CD3 bispecific and masked antibodies against MUC16, both for solid tumors. These breakthroughs validate the broader potential of conditionally activated bispecifics in oncology. Collaboration and innovation pave the way for safer, more effective cancer treatments. Let’s keep pushing the boundaries of what’s possible! Read more here: https://bit.ly/3BqMFMR #iBio #BioTech #ImmunoOncology #BiotechInnovation #MachineLearning #AntibodyEngineering